30 articles in this topic
A 260-infant RCT tests whether adding bleomycin injections to low-dose propranolol accelerates hemangioma regression and improves skin outcomes.
A landmark effort to bank immune-compatible stem cells matched to the majority of the US population — now terminated.
A phase 1 dose-escalation trial tests the safety of AAV-delivered ND4 gene therapy in patients with Leber's hereditary optic neuropathy.
NHLBI researchers optimize collection and storage of umbilical cord blood from sickle cell-affected and healthy newborns for future stem cell therapies.
A Phase 1/2 trial of NFS-02 gene therapy for LHON-associated vision loss was terminated before completion, raising questions about mitochondrial gene therapy.
A completed multicenter feasibility trial evaluates BTM, a novel biodegradable scaffold, for treating serious deep burn injuries.
A 12-month RCT compares three scaffold types and two EDTA concentrations for regenerating necrotic immature permanent teeth.
NIDCR researchers compared stromal cells from bone marrow, skin, spleen, and fat to identify which best regenerates bone and supports blood formation.
A Phase 2 trial evaluates MBA-P01, a novel botulinum toxin A, for safety and optimal dosing in treating frown lines.
A Phase 1/2 trial tests four rounds of intrathecal MSC injections in ALS patients, targeting both safety and disease progression.
A terminated multicenter RCT examined whether mechanical cough assistance plus NIV could cut re-intubation rates in ICU patients with weak cough.
Small trial tests autologous bronchial stem cells to repair damaged lung tissue in chronic obstructive pulmonary disease patients.
